Table 5.
Comparison of the measurements of the pulmonary function tests at 12 months based on the completion of the therapy.
| Baseline | n | 12 Months | n | p | |
|---|---|---|---|---|---|
| Full dose | |||||
| FVC | 74.0 (66.0–81.0) | 17 | 66.0 (61.0–82.0) | 11 | 0.975 |
| DLCO | 44.0 (35.0–58.5) | 18 | 44.0 (29.8–53.8) | 12 | 0.098 |
| Reduced dose | |||||
| FVC | 81.0 (68.0–87.5) | 10 | 81.0 (77.0–89.0) | 7 | 0.880 |
| DLCO | 46.0 (38.0–58.0) | 8 | 38.5 (37.3–50.3) | 6 | 0.084 |
| Suspended | |||||
| FVC | 70.0 (59.0–82.0) | 13 | 55.0 (52.8–66.3) | 8 | 0.035 |
| DLCO | 43.0 (31.8–50.5) | 12 | 37.5 (31.0–55.3) | 6 | 0.350 |
Data are presented as median (IQR). FVC: forced vital capacity; and DLCO: diffusing capacity of the lungs for carbon monoxide.